The Medical Letter on Drugs and Therapeutics
Drug Interaction: Dabigatran (Pradaxa) and Statins
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The results of a recently published study suggest that taking the oral direct thrombin inhibitor dabigatran etexilate (Pradaxa) with either simvastatin (Zocor, and others) or lovastatin (Altoprev, and others) increases the risk of major hemorrhage.1

POSSIBLE MECHANISMS — The mechanism for this potential interaction has not been established. Dabigatran etexilate is a substrate of the transporter P-glycoprotein (P-gp); drugs that inhibit P-gp could increase dabigatran serum concentrations and the risk of bleeding.2 In in vitro studies, simvastatin and lovastatin have been shown to inhibit P-gp3; however, limited data from in vivo studies suggest simvastatin and lovastatin have little to no effect on serum concentrations of P-gp substrates such as digoxin. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Drug Interaction: Dabigatran (Pradaxa) and Statins
Article code: 1513e
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian